Last reviewed · How we verify
NCT03624842
Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease
trial testing Trappsol (R) Cyclo (TM) in Late Onset Alzheimer Disease. No longer available.
Quick facts
| Lead sponsor | Cyclo Therapeutics, Inc. |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Trappsol (R) Cyclo (TM) — full drug profile →
Conditions studied
- Late Onset Alzheimer Disease — all drugs for Late Onset Alzheimer Disease →
Sponsor
Cyclo Therapeutics, Inc. — full company profile →
Who can join
Eligibility, any sex, with Late Onset Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To afford urgent access to a potential-disease modifying treatment, Dr. Diana Kerwin, in partnership with CTD Holdings, the manufacturer of Trappsol (R) Cyclo(TM), will administer the product to a patient with Alzheimer's Disease who has no other disease-modifying treatment options.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03624842
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Late Onset Alzheimer Disease
Currently open trials in the same condition.
- NCT04838301 — Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease · Phase 2 · recruiting
Other Cyclo Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05607615 — A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease · Phase 2 · unknown
- NCT02939547 — Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1) · Phase 1 · completed
- NCT02912793 — Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03624842 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cyclo Therapeutics, Inc.
- Last refreshed: 10 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03624842.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing